Systematic review: The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy

Rohit Loomba, Ayana Rowley, Robert Wesley, T. Jake Liang, Jay H. Hoofnagle, Frank Pucino, Gyorgy Csako

Research output: Contribution to journalArticle

Abstract

Background: Lamivudine is increasingly being used to prevent hepatitis B reactivation in patients with cancer who test positive for hepatitis B surface antigen (HBsAg) and are undergoing chemotherapy. Purpose: To determine whether preventive lamivudine reduces chemotherapy-induced hepatitis B virus (HBV)-related morbidity and mortality in patients with cancer who test positive for HBsAg. Data Sources: MEDLINE, Ovid MEDLINE, TOXNET, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials were searched in all languages until June 2007. Study Selection: Clinical trials and cohort studies that reported the efficacy of preventive lamivudine versus control on HBV reactivation in patients who tested positive for HBsAg and were receiving chemotherapy were included. Additional requirements included minimum sample size (>5 participants per treatment group) and reported HBV-related morbidity and mortality data. Data Extraction: Two investigators independently did literature searches and data extraction, and 2 other investigators independently confirmed study eligibility and data retrieval. Data Synthesis: Fourteen studies (2 randomized, controlled trials; 8 prospective cohort studies; and 4 retrospective cohort studies) met the predefined criteria for analysis. There were 275 patients in the preventive lamivudine group and 475 control participants for the primary end point of HBV reactivation. With preventive lamivudine, the relative risk for both HBV reactivation and HBV-related hepatitis ranged from 0.00 to 0.21. None of the patients in the preventive lamivudine group developed HBV-related hepatic failure (0 of 108 patients vs. 21 of 162 patients), and only 4 deaths were attributable to HBV (4 of 208 patients vs. 27 of 394 patients) in the preventive lamivudine group. Lamivudine was well tolerated, and no adverse effects were noted. Limitations: The studies included in the meta-analysis did not consistently report all of the outcomes of interest. Sample sizes were small and only 2 studies had a randomized, controlled design. Conclusion: Preventive therapy with lamivudine for patients who test positive for HBsAg and are undergoing chemotherapy may reduce the risk for HBV reactivation and HBV-associated morbidity and mortality.

Original languageEnglish (US)
Pages (from-to)519-528
Number of pages10
JournalAnnals of Internal Medicine
Volume148
Issue number7
StatePublished - Apr 1 2008
Externally publishedYes

Fingerprint

Lamivudine
Hepatitis B
Hepatitis B virus
Drug Therapy
Hepatitis B Surface Antigens
Cohort Studies
Information Storage and Retrieval
Morbidity
MEDLINE
Sample Size
Mortality
Research Personnel
Liver Failure
Hepatitis
Meta-Analysis
Neoplasms
Language
Randomized Controlled Trials
Retrospective Studies
Clinical Trials

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Loomba, R., Rowley, A., Wesley, R., Liang, T. J., Hoofnagle, J. H., Pucino, F., & Csako, G. (2008). Systematic review: The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Annals of Internal Medicine, 148(7), 519-528.

Systematic review : The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. / Loomba, Rohit; Rowley, Ayana; Wesley, Robert; Liang, T. Jake; Hoofnagle, Jay H.; Pucino, Frank; Csako, Gyorgy.

In: Annals of Internal Medicine, Vol. 148, No. 7, 01.04.2008, p. 519-528.

Research output: Contribution to journalArticle

Loomba, R, Rowley, A, Wesley, R, Liang, TJ, Hoofnagle, JH, Pucino, F & Csako, G 2008, 'Systematic review: The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy', Annals of Internal Medicine, vol. 148, no. 7, pp. 519-528.
Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F et al. Systematic review: The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Annals of Internal Medicine. 2008 Apr 1;148(7):519-528.
Loomba, Rohit ; Rowley, Ayana ; Wesley, Robert ; Liang, T. Jake ; Hoofnagle, Jay H. ; Pucino, Frank ; Csako, Gyorgy. / Systematic review : The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. In: Annals of Internal Medicine. 2008 ; Vol. 148, No. 7. pp. 519-528.
@article{5d856c5172ca4bb7a8de58353f5ae7b4,
title = "Systematic review: The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy",
abstract = "Background: Lamivudine is increasingly being used to prevent hepatitis B reactivation in patients with cancer who test positive for hepatitis B surface antigen (HBsAg) and are undergoing chemotherapy. Purpose: To determine whether preventive lamivudine reduces chemotherapy-induced hepatitis B virus (HBV)-related morbidity and mortality in patients with cancer who test positive for HBsAg. Data Sources: MEDLINE, Ovid MEDLINE, TOXNET, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials were searched in all languages until June 2007. Study Selection: Clinical trials and cohort studies that reported the efficacy of preventive lamivudine versus control on HBV reactivation in patients who tested positive for HBsAg and were receiving chemotherapy were included. Additional requirements included minimum sample size (>5 participants per treatment group) and reported HBV-related morbidity and mortality data. Data Extraction: Two investigators independently did literature searches and data extraction, and 2 other investigators independently confirmed study eligibility and data retrieval. Data Synthesis: Fourteen studies (2 randomized, controlled trials; 8 prospective cohort studies; and 4 retrospective cohort studies) met the predefined criteria for analysis. There were 275 patients in the preventive lamivudine group and 475 control participants for the primary end point of HBV reactivation. With preventive lamivudine, the relative risk for both HBV reactivation and HBV-related hepatitis ranged from 0.00 to 0.21. None of the patients in the preventive lamivudine group developed HBV-related hepatic failure (0 of 108 patients vs. 21 of 162 patients), and only 4 deaths were attributable to HBV (4 of 208 patients vs. 27 of 394 patients) in the preventive lamivudine group. Lamivudine was well tolerated, and no adverse effects were noted. Limitations: The studies included in the meta-analysis did not consistently report all of the outcomes of interest. Sample sizes were small and only 2 studies had a randomized, controlled design. Conclusion: Preventive therapy with lamivudine for patients who test positive for HBsAg and are undergoing chemotherapy may reduce the risk for HBV reactivation and HBV-associated morbidity and mortality.",
author = "Rohit Loomba and Ayana Rowley and Robert Wesley and Liang, {T. Jake} and Hoofnagle, {Jay H.} and Frank Pucino and Gyorgy Csako",
year = "2008",
month = "4",
day = "1",
language = "English (US)",
volume = "148",
pages = "519--528",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "7",

}

TY - JOUR

T1 - Systematic review

T2 - The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy

AU - Loomba, Rohit

AU - Rowley, Ayana

AU - Wesley, Robert

AU - Liang, T. Jake

AU - Hoofnagle, Jay H.

AU - Pucino, Frank

AU - Csako, Gyorgy

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Background: Lamivudine is increasingly being used to prevent hepatitis B reactivation in patients with cancer who test positive for hepatitis B surface antigen (HBsAg) and are undergoing chemotherapy. Purpose: To determine whether preventive lamivudine reduces chemotherapy-induced hepatitis B virus (HBV)-related morbidity and mortality in patients with cancer who test positive for HBsAg. Data Sources: MEDLINE, Ovid MEDLINE, TOXNET, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials were searched in all languages until June 2007. Study Selection: Clinical trials and cohort studies that reported the efficacy of preventive lamivudine versus control on HBV reactivation in patients who tested positive for HBsAg and were receiving chemotherapy were included. Additional requirements included minimum sample size (>5 participants per treatment group) and reported HBV-related morbidity and mortality data. Data Extraction: Two investigators independently did literature searches and data extraction, and 2 other investigators independently confirmed study eligibility and data retrieval. Data Synthesis: Fourteen studies (2 randomized, controlled trials; 8 prospective cohort studies; and 4 retrospective cohort studies) met the predefined criteria for analysis. There were 275 patients in the preventive lamivudine group and 475 control participants for the primary end point of HBV reactivation. With preventive lamivudine, the relative risk for both HBV reactivation and HBV-related hepatitis ranged from 0.00 to 0.21. None of the patients in the preventive lamivudine group developed HBV-related hepatic failure (0 of 108 patients vs. 21 of 162 patients), and only 4 deaths were attributable to HBV (4 of 208 patients vs. 27 of 394 patients) in the preventive lamivudine group. Lamivudine was well tolerated, and no adverse effects were noted. Limitations: The studies included in the meta-analysis did not consistently report all of the outcomes of interest. Sample sizes were small and only 2 studies had a randomized, controlled design. Conclusion: Preventive therapy with lamivudine for patients who test positive for HBsAg and are undergoing chemotherapy may reduce the risk for HBV reactivation and HBV-associated morbidity and mortality.

AB - Background: Lamivudine is increasingly being used to prevent hepatitis B reactivation in patients with cancer who test positive for hepatitis B surface antigen (HBsAg) and are undergoing chemotherapy. Purpose: To determine whether preventive lamivudine reduces chemotherapy-induced hepatitis B virus (HBV)-related morbidity and mortality in patients with cancer who test positive for HBsAg. Data Sources: MEDLINE, Ovid MEDLINE, TOXNET, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials were searched in all languages until June 2007. Study Selection: Clinical trials and cohort studies that reported the efficacy of preventive lamivudine versus control on HBV reactivation in patients who tested positive for HBsAg and were receiving chemotherapy were included. Additional requirements included minimum sample size (>5 participants per treatment group) and reported HBV-related morbidity and mortality data. Data Extraction: Two investigators independently did literature searches and data extraction, and 2 other investigators independently confirmed study eligibility and data retrieval. Data Synthesis: Fourteen studies (2 randomized, controlled trials; 8 prospective cohort studies; and 4 retrospective cohort studies) met the predefined criteria for analysis. There were 275 patients in the preventive lamivudine group and 475 control participants for the primary end point of HBV reactivation. With preventive lamivudine, the relative risk for both HBV reactivation and HBV-related hepatitis ranged from 0.00 to 0.21. None of the patients in the preventive lamivudine group developed HBV-related hepatic failure (0 of 108 patients vs. 21 of 162 patients), and only 4 deaths were attributable to HBV (4 of 208 patients vs. 27 of 394 patients) in the preventive lamivudine group. Lamivudine was well tolerated, and no adverse effects were noted. Limitations: The studies included in the meta-analysis did not consistently report all of the outcomes of interest. Sample sizes were small and only 2 studies had a randomized, controlled design. Conclusion: Preventive therapy with lamivudine for patients who test positive for HBsAg and are undergoing chemotherapy may reduce the risk for HBV reactivation and HBV-associated morbidity and mortality.

UR - http://www.scopus.com/inward/record.url?scp=42249113025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42249113025&partnerID=8YFLogxK

M3 - Article

C2 - 18378948

AN - SCOPUS:42249113025

VL - 148

SP - 519

EP - 528

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 7

ER -